DLBCL and Extranodal Disease
A re-evaluation of the clinical significance of extranodal disease among patients with diffuse large B-cell lymphoma (DLBCL) who were staged with positron emission tomography/computed tomography was undertaken to determine the prognostic impact of extranodal disease.
Results were presented at the 2014 American Society of Hematology annual meeting. Patients (n = 444) from Denmark and Canada were included in this retrospective study. Extranodal disease was diagnosed in 286 (64%) patients. Patients with one or two extranodal sites of involvement had a similar outcome: three-year progression-free survival was 68% versus 70%; patients with involvement of more than three extranodal sites had progressed.
Click here for the full article.